



HbA1c – SHORT TERM PREDICTOR OF MORTALITY IN NON DIABETIC ST ELEVATION MYOCARDIAL INFARCTION PATIENTS

Cardiology

| | |
|--------------------------------|---|
| Dr.Prem Krishna Anandan | M.D., MRCP., DNB., DM, Asst Professor, Department Of Cardiology, PSG Hospitals, Peelamedu, Coimbatore |
| Dr.K.Tamilarasu* | M.D.,DNB., Associate Professor, Department Of Cardiology,PSG Hospitals, Peelamedu, Coimbatore *Corresponding Author |
| Dr.G.Rajendran | M.D.,D.M., Professor and Head, Department Of Cardiology,PSG Hospitals, Peelamedu, Coimbatore |
| Dr.Shanmuga Sundaram | M.D.,D.M., Professor, Department Of Cardiology, PSG Hospitals, Peelamedu, Coimbatore |
| Dr.P.Ramasamy | M.D.,DNB., Associate Professor, Department Of Cardiology,PSG Hospitals, Peelamedu, Coimbatore |
| Dr.R.B.Vidyakar | M.D.,D.M., Asst Professor, Department Of Cardiology,PSG Hospitals, Peelamedu, Coimbatore |

ABSTRACT

BACKGROUND: Acute glycometabolic derangement in non-diabetic patients with acute myocardial infarction (AMI) has been reported with discrepant prognostic results. The aim of the present study was to assess the prognostic impact of glycated haemoglobin (HbA1c) levels, reflecting long-term glycometabolic disturbance, in a population of patients without known diabetes mellitus.

METHODS: We examined 300 consecutive prospective patients diagnosed with AMI and unknown diabetes mellitus. We analysed metabolic function as a stratified variable using three groups of patients according to HbA1c: Group 1 (<5.5%): 111 patients (37%); Group 2 (5.5 to 6.4%): 168 patients (56%); Group 3 (>6.4%): 21 patients (7%). Association between HbA1c groups and classic cardiovascular risk factor and in-hospital outcomes were assessed through univariate and multivariate analysis.

RESULTS: In-hospital mortality was 5% (16/300 patients). Higher HbA1c was associated with poor glycometabolic control, older patients, obesity, hypertension, Killip's class>1, increased heart rate, initial bundle branch block, atrial fibrillation and higher mortality during follow-up. In a multivariate adjusted risk, in-hospital mortality was associated with age (odds ratio (OR)= 1.056; 1–1.1; p=0.006), Killip's class>1 (OR=2.4; 1–6.1; p=0.05) and HbA1c (OR=1.5; 1.15–1.9; p=0.002). Hypertension (OR=0.39; 0.18–0.87; p=0.022) and angiotensin-converting enzyme inhibitors (OR=0.28; 0.12–0.69; p=0.005) were protective factors.

CONCLUSIONS: HbA1c is an important risk marker in the absence of a history of diabetes mellitus in patients with AMI. The optimal management strategy in these patients may contribute to decreased in-hospital mortality.

KEYWORDS

Acute myocardial infarction, admission glycaemia, diabetes mellitus, glycated haemoglobin (HbA1c)

INTRODUCTION

In recent years, much attention has been paid to the glycometabolism of patients with coronary artery disease. Measurement of admission glucose and glycated haemoglobin (HbA1c) levels in acute myocardial infarction (AMI) may identify patients with disturbed glucose metabolism and an increased risk for adverse outcome[1–4]. Although HbA1c and glucose are related, they can differentiate between mechanisms of adverse outcome.

Hyperglycaemia for most patients with AMI is a manifestation of previous disturbed glucose metabolism; it is also partially caused by acute stress with raised levels of cortisol[5–7]. HbA1c level is an indicator of average blood glucose concentrations over the preceding 2–3 months, which is a convenient and well-known biomarker in clinical practice, using the HbA1c assay as the preferred method for diabetes diagnosis and treatment control[8]. HbA1c is minimally affected by stress hyperglycaemia during AMI and therefore reflects previous glycometabolic disturbance.

Recent studies that evaluated the prognostic value of HbA1c in patients hospitalized with advanced atherosclerosis have reported discrepant results. Several studies showed that although crude mortality data was higher in patients with elevated HbA1c following adjustment for many cardiovascular risk factors, HbA1c values failed to predict in-hospital mortality[9–11]. Other authors have observed that HbA1c, as a surrogate for more chronic dysglycaemia, is a more useful marker of patients with greater long-term risk of death[12–16]

Because the prognostic value of HbA1c levels in patients with acute coronary syndromes had different prognostic effects based on patient's diabetes status and only smaller studies exist with different methods and results, the purpose of the present study was therefore to assess

whether the HbA1c levels have a prognostic significance and could be used in short-term risk stratification in patients with AMI and unknown diabetes mellitus (DM).

MATERIAL AND METHODS

Patient population

We performed a single-centre observational prospective study including 300 patients with AMI admitted into the coronary care unit (CCU). The inclusion period was March 2016 to March 2018. The study was approved by the local ethical committee and all patients included gave informed consent to participate in the study.

INCLUSION CRITERIA:

- 1] chest pain with ST segment elevation or depression of at least 1 mm in one or more peripheral leads of the ECG and/or at least 2 mm in one or more precordial leads, or
- 2] acute left bundle branch block, or
- 3] elevated levels of troponin according to the criteria established by current guidelines[17]

All patients received recommended standard management for AMI.

EXCLUSION CRITERIA

- 1] anaemia
- 2] acute inflammatory diseases
- 3] hepatic failure
- 4] autoimmunity
- 5] cancer and
- 6] patients with chronic renal failure in a haemodialysis programme
- 7] known DM

DM was defined as a history of diabetes according to medical history

obtained from hospital records or when the patient reported receiving pharmacological treatment with oral hypoglycaemic drugs or insulin. The present analysis is based on data from 300 AMI patients who were not previously diagnosed DM. Because milder abnormalities of glucose control (below the diagnostic threshold of DM) are associated with increased cardiovascular risk, patients were graded into three categories or groups according to baseline admission levels of HbA1c: HbA1c levels < 5.5%, 5.5–6.4%, >6.4%.

METHODS

The project design included a medical examination, biochemical analyses and instrumental exams as well as echocardiography and coronary angiography results. The presence and degree of heart failure were assessed on admission at the emergency department, following the Killip classification[18]. Among the main cardiovascular risk factors, the presence of hypertension, type II diabetes, dyslipidaemia, smoking habits and body mass index were considered. The Global Registry of Acute Coronary Events (GRACE) risk model was obtained to predict probability of hospital death and the level of risk for individual patients.

All patients received recommended standard management for AMI with regard to thrombolytic therapy, aspirin, clopidogrel, low-molecular-weight heparin, glycoprotein IIb/IIIa inhibitors, beta-blockers, statins and angiotensin-converting enzyme inhibitors (ACEis), as appropriate. All analyses were measured by conventional laboratory methods. In the CCU department the following analyses were collected: serum glucose, glycated haemoglobin, white blood cell count, platelets, haematocrit, electrolytes and cardiac biomarkers (troponin). HbA1c was analysed by ion-exchange high-performance liquid chromatography using the ADAMS HA-8180 analyser (Arkray Corp., Kyoto, Japan)[19]

In all patients coronary angiography was performed as soon as possible, and the number of coronary arteries damaged evaluated. Patients with STEMI received thrombolytic therapy at the beginning of the study. Patients with contraindications for thrombolytic therapy were taken for urgent invasive angiography with the intention of performing primary PCI. Moreover, in cases of unsuccessful fibrinolytic therapy, patients received rescue PCI. Left ventricular ejection fraction (LVEF) was assessed through two-dimensional echocardiography immediately after admission.

Continuous monitoring was performed in all patients during their stay at the CCU in order to determine any type of significant arrhythmia. After discharge from the CCU, an electrocardiogram was performed daily and when patients had symptoms.

STATISTICAL ANALYSIS

Baseline characteristics of the study population were calculated according to categories of glycated haemoglobin values. We analysed HbA1c function as a continuous and also as a stratified variable. Continuous data were summarized and given as median values with corresponding SD or SEM, and dichotomous data were given as counts and percentages. The Kruskal–Wallis test was used for categorical characteristics with more than two groups. Means between groups were compared by the use of independent-samples t-tests (ANOVA polynomial linear term). In multivariate analysis (Cox regression using forward stepwise variable selection methods), the association of HbA1c with the statistical significance variables and outcome (in-hospital mortality) were adjusted for age, sex, classical cardiovascular risk factors, Killip class, history of previous myocardial infarction, serum creatinine, serum glycaemia, systolic blood pressure and heart rate on admission.

All statistical tests were performed with SPSS 19.0. A value of $p < 0.05$ was considered statistically significant.

RESULTS

Baseline characteristics

300 patients without prior diagnostic of DM were included in our study population (Figure 1). Three categories of patients were created according to HbA1c level: Group 1 (< 5.5%): 111 patients (37%); Group 2 (5.5 to 6.4%): 168 patients (56%); Group 3 (>6.4%): 21 patients (7%).

Baseline characteristics of the study population are shown in Table 1. The mean age of our sample was 62 ± 13 years and 78% were males. In

the subgroups analysis, patients with higher HbA1c were older; more often had a history of hypertension (48% vs. 59% vs. 71%) and arteriopathy (4% vs. 5% vs. 12%). STEMI was present in 208 patients (69%). Killip class >1, glycaemia were associated with higher HbA1c levels. The mortality in the global group was 5% (16 patients). Table 2 describes the outcomes and treatment according to HbA1c categories.

Multivariate analysis is shown in Table 3. The baseline covariates included in the final model associated with mortality were Killip >1, age and HbA1c levels. A history of hypertension and pharmacological therapy with ACEis had a protective effect and was inversely associated.

DISCUSSION

We found a substantial proportion of patients suffering from AMI with underlying prediabetes and unknown overt DM after hospital admission. These patients with disturbed glucose metabolism had worse early outcomes, characterized by progressive increased rates of in-hospital mortality according to HbA1c. In hospital mortality was 14% in patients with HbA1c >6.4%.

The relationship between admission hyperglycaemia (stress hyperglycaemia) and short-term mortality in subjects without known DM after AMI has been well documented. Increased glucose levels on admission conferred an almost four-fold risk of death in patients without known DM after an AMI and two-fold risk in patients with STEMI additive to classical risk factor parameters[6]. HbA1c level is a stable indicator of unstressed long-term glucose control and is more useful to predict abnormal glucose tolerance in AMI patients compared with admission glucose[5]. HbA1c is less influenced than plasma glucose by acute stress and illness[20,21]

For many patients, the AMI hospitalization represents a period in which previously unrecognized DM could be initially diagnosed. Indeed, in our study 7% of patients met the HbA1c criteria for newly diagnosed DM[8] and this group represents a particularly high-risk population that has not been recognized or treated. The frequency of 7% non-diabetic patients with elevated HbA1c found in the current study is compatible with the findings of undiagnosed diabetes in other studies[5,20,21]

Recent studies that evaluated the prognostic value of HbA1c in patients hospitalized with acute coronary syndrome have reported discrepant results. Several studies showed that although crude mortality data were higher in patients with elevated HbA1c following adjustment for many cardiovascular risk factors, HbA1c values failed to be an independent factor for mortality[9–11].

HbA1c, as a surrogate for more chronic dysglycaemia, is a more useful marker of patients with greater long-term risk of death[12,13]. However, other authors suggested that HbA1c level was also a potent predictor of both in-hospital and long-term mortality[14–16]. Mortality rate and the risk of cardiogenic shock increased with levels of HbA1c in 150 patients with AMI without history of diabetes in an earlier study, which did not present a multivariate analysis[20]. After systematic review in patients with coronary artery disease with and without recognized diabetes, Liu et al[22] found that HbA1c levels had different prognostic effects based on patients' diabetes status. A U-shaped relationship, with lower mortality among patients within the prediabetes range, has been observed.

Glycometabolic disturbance per se has a pathophysiological role in determining cardiovascular outcome, which is still disputed. The current data and their analyses do not elucidate whether the glucose disturbance has a causal role or is just a marker of more severe disease. For coronary heart disease, measures of risk discrimination showed significant improvement when glycated haemoglobin was added to models including fasting glucose[23]. Yet, undiagnosed diabetes or impaired glucose tolerance might be associated with other cardiovascular risk factors that are also undiagnosed and therefore untreated. Several mechanisms would have been involved in the greater early mortality among patients with AMI and previously undiagnosed diabetes. The fact that HbA1c was an independent prognostic indicator in our patients, additive to initial heart failure and classical cardiovascular risk factors, suggests the possibility that it was an important outcome factor, rather than a simple consequence of a larger or smaller infarct size.

Elevated HbA1c levels are likely the result of long term insulin

resistance (HOMA). Metabolic disturbances associated with insulin resistance, including metabolic syndrome, abolish the effect of ischaemic preconditioning and induce oxidative stress affecting platelet function, coagulation and fibrinolysis[24,25]. It is known that hyperglycaemia and/or hyperinsulinaemia in the acute stage of myocardial infarction are predictors of impaired coronary flow, both before and after reperfusion therapy with the occurrence of a non-reflow phenomenon after angioplasty[26–28].

An interesting observation in previous works[6,29] is the association between hyperglycaemia and the high risk of ventricular tachyarrhythmia and initial or complicated bundle branch block in patients with AMI regardless of diabetes status. The use of free fatty acids instead of glucose by the ischemic myocardium could precipitate regional oxygen or energy crisis, and may lead to damaged cardiac-cell membranes, calcium overload and arrhythmias preceding mortality in many patients[30–32]. In this study we have only observed an association between atrial fibrillation and bundle branch block with HbA1c levels but these factors were not independent risk adjusted for in-hospital mortality.

Hypertension is a well-established risk factor for cardiovascular disease. The prognosis for hypertensive patients after AMI is uncertain because of the sparse and somewhat contradictory data. Patients with prior hypertension are older and are more likely to have diabetes and renal dysfunction. These clinical characteristics are all predictors of poor outcome[33,34]. The more risk factors present, the greater the likelihood of developing death and morbidity. Nevertheless, recent studies have shown a better in-hospital outcome in hypertensive than in normotensive patients with AMI. Abrignani et al[35], observed in 4994 consecutive patients admitted to an intensive care unit that hypertensive subjects with first AMI have a better in-hospital outcome than age- and gender-matched normotensive subjects, perhaps due to a less severe extension of the infarction area or to a different pathophysiological mechanism. Using data from the GRACE risk score in patients with non-ST-segment elevation acute coronary syndrome, Lee et al[36] observed that prior hypertension and the number of antihypertensive medications used pre-admission were not associated with increased in-hospital mortality. Patients with prior hypertension presented with higher systolic blood pressure on admission than those without; therefore one might expect these patients to have lower in-hospital mortality than those without prior history of hypertension. Our findings confirm the powerful and robust

protective prognostic significance of hypertension in patients with AMI and unknown diabetes (odds ratio = 0.39; confidence interval: 0.18–0.87). Because milder abnormalities of glucose control are associated with increased cardiovascular risk, patients with diagnosis of diabetes were not considered for this study. Only 7% of our patients with HbA1c >6.4% could be considered as 'true diabetic patients'.

STUDY LIMITATIONS

Despite using multivariable adjustment to account for baseline confounders, residual confounding cannot be excluded.

When the HbA1c cutoff value of >6.4%, as suggested by the American Diabetes Association was used, 7% of our population could readily be diagnosed on admission as undiagnosed DM. These patients were not excluded from our study because DM was defined as known diabetic status on admission before HbA1c was obtained. So, the two groups that this small group was compared with had much higher representation in the study population. These patients must be considered as higher risk patients because they had elevated in-hospital mortality (14%).

This observational study evaluated a clinical population of AMI patients expected to undergo early invasive treatment (99%), and results may not be applicable to all AMI populations.

CONCLUSION

We found that HbA1c level, as a surrogate for more chronic dysglycaemia, is a useful marker of short-term risk of death in AMI patients without a history of diabetes. Introducing measurement of HbA1c in the CCU seems to be a simple method to obtain important information on mortality risk.

Table 1: Baseline subject characteristics according to HbA1c group and global population.

| | Total patients | HbA1c Group 1 <5.5% | HbA1c Group 2 5.5%–6.4% | HbA1c Group 3 > 6.4% | P value |
|---------------|----------------|---------------------|-------------------------|----------------------|---------|
| Patients | 300 | 111(37%) | 168 (56%) | 21 (7%) | |
| Female (%) | 22 | 23 | 21 | 19 | NS |
| Aged (M ± SD) | 62 ± 13 | 60 ± 13 | 64 ± 13 | 64 ± 13 | 0.007 |
| BMI (kg/m2) | 27 ± 4 | 26 ± 3 | 28 ± 4 | 29 ± 3 | <0.001 |

TABLE 2 BASELINE CHARACTERISTICS

| | Total patients | HbA1c Group 1 <5.5% | HbA1c Group 2 5.5%–6.4% | HbA1c Group 3 > 6.4% | P value |
|------------------------------------|----------------|---------------------|-------------------------|----------------------|---------|
| Patients | 300 | 111 (37%) | 168 (56%) | 21 (7%) | |
| NYHA>2 (%) | 19 | 16 | 20 | 24 | ns |
| Hypertension (%) | 55 | 48 | 59 | 71 | 0.001 |
| Previous myocardial infarction (%) | 19 | 19 | 19 | 17 | ns |
| smoker (%) | 49 | 54 | 45 | 57 | ns |
| Dyslipidaemia (%) | 45 | 46 | 43 | 57 | ns |
| Peripheral arteriopathy (%) | 5 | 4 | 5 | 12 | 0.005 |
| Prior PCI | 12 | 15 | 10 | 12 | ns |

TABLE 3 BASELINE CHARACTERISTICS

| | Total patients | HbA1c Group 1 <5.5% | HbA1c Group 2 5.5%–6.4% | HbA1c Group 3 > 6.4% | P value |
|-------------------|----------------|---------------------|-------------------------|----------------------|---------|
| Patients | 300 | 111 (37%) | 168 (56%) | 21 (7%) | |
| STEMI(%) | 69 | 68 | 72 | 62 | ns |
| Killip > I (%) | 19 | 14 | 21 | 31 | 0.004 |
| HR (%) | 79 ± 22 | 79 ± 20 | 78 ± 21 | 89 ± 29 | 0.01 |
| SBP (%) | 135 ± 32 | 135 ± 30 | 134 ± 34 | 146 ± 34 | ns |
| LVEF(%) | 51 ± 11 | 52 ± 11 | 51 ± 11 | 50 ± 14 | ns |
| >I Vessel disease | 34 | 32 | 34 | 41 | ns |
| PCI | 99 | 90 | 97 | 93 | ns |

TABLE 4 AVERAGE HbA1c and eGFR

| | Total patients | HbA1c Group 1 <5.5% | HbA1c Group 2 5.5%–6.4% | HbA1c Group 3 > 6.4% | P value |
|------------------------------------|----------------|---------------------|-------------------------|----------------------|---------|
| Patients | 300 | 111(37%) | 168 (56%) | 21 (7%) | |
| Admission glucose (mg/dl) (M ± SD) | 144±59 | 137 ± 64 | 142± 47 | 200 ± 90 | 0.001 |
| eGFR (ml/min) (M ± SD) | 68 ± 30 | 69 ± 28 | 68 ± 32 | 63 ± 23 | ns |
| HbA1c (%) (M ± SD) | 5.8 ± 0.7 | 5.2 ± 0.3 | 5.9 ± 0.2 | 7.6 ± 1.5 | 0.001 |

Table 5. Hospital adverse outcomes and in-hospital therapies

| | Total patients | HbA1c Group 1 <5.5% | HbA1c Group 2 5.5%–6.4% | HbA1c Group 3 > 6.4% | P value |
|---|----------------|---------------------|-------------------------|----------------------|---------|
| Patients | 301 | 111 (37%) | 168 (56%) | 21 (7%) | |
| GRACE risk score (M±SD) | 159 ± 43 | 154 ± 41 | 162 ± 42 | 163 ± 58 | |
| In-hospital mortality (16 pts) (%) | 5 | 4 | 5 | 14 | 0.02 |
| Atrial fibrillation (71 pts) (%) | 12 | 6 | 15 | 19 | 0.001 |
| Initial BBB (42 pts) (%) | 7 | 3 | 9 | 10 | 0.01 |
| Primary ventricular fibrillation (36 pts) (%) | 6 | 4 | 7 | 4 | |
| AV block ≥2° (34 pts) (%) | 6 | 5 | 6 | 7 | |
| In-coronary care unit (days) | 3 | 3 | 4 | 4 | |
| In-hospital stay (days) (median) | 7 | 8 | 8 | 9 | |

TABLE 6: HOSPITAL THERAPIES

| | Total | Group 1 | Group 2 | Group 3 | P value |
|---------------------------------|-------|---------|---------|---------|---------|
| Reperfusion therapy (STEMI) (%) | 69 | 60 | 75 | 73 | 0.006 |
| Dual antiplatelet treatment (%) | 98 | 96 | 99 | 100 | 0.03 |
| Beta-blockers (%) | 41 | 42 | 40 | 41 | NS |
| ACE inhibitors (%) | 62 | 62 | 62 | 62 | NS |
| Statin (%) | 95 | 95 | 95 | 93 | NS |
| Diuretics (%) | 22 | 21 | 21 | 41 | NS |
| Inotropic agents (%) | 9 | 6 | 10 | 12 | NS |
| Insulin (%) | 8 | 3 | 7 | 41 | <0.001 |

Table 7. Multivariate adjusted risk for in-hospital mortality.

| OR | 95% CI | p value | |
|----------------|--------|-----------|-------|
| Age | 1.056 | 1–1.1 | 0.006 |
| Hypertension | 0.395 | 0.18–0.87 | 0.022 |
| HbA1C | 1.493 | 1.15–1.9 | 0.002 |
| Killip > 1 | 2.44 | 1–6.1 | 0.05 |
| ACE inhibitors | 0.28 | 0.12–0.69 | 0.005 |

ROC CURVE FOR MORTALITY:




Table 8: ROC CURVE VARIABLES:

| S.NO | HbA1c | SENSITIVITY | SEPECIFICITY |
|------|-------|-------------|--------------|
| 1 | ≥4 | 100 | 0 |
| 2 | ≥4 | 100 | 2.44 |
| 3 | ≥4.5 | 100 | 14.63 |
| 4 | ≥5.1 | 100 | 56.10 |
| 5 | ≥5.4 | 100 | 73.17 |
| 6 | ≥5.9 | 66.67 | 85.37 |
| 7 | ≥6.3 | 44.44 | 90.24 |
| 8 | ≥6.6 | 33.33 | 97.56 |
| 9 | ≥6.9 | 11.11 | 100 |
| 10 | ≥7.1 | 0 | 100 |

From the table it is clear that HbA1c >5.4 have 100% sensitivity and 73% specificity in predicting mortality.

REFERENCES

- Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: A systematic overview. *Lancet* 2000; 355: 773–778.
- Stranders I, Diamant M, Van Gelder R, et al. Admission blood glucose level as risk indicator of death after myocardial infarction in patients with and without diabetes mellitus. *Arch Intern Med* 2004; 164: 982–988.
- Selvin E, Steffes MW, Zhu H, et al. Glycated hemoglobin, diabetes, and cardiovascular

- risk in nondiabetic adults. *N Engl J Med* 2010; 362: 800–811.
- Hadjadj S, Coisne D, Maucó G, et al. Prognostic value of admission plasma glucose and HbA1c in acute myocardial infarction. *Diabet Med* 2004; 21: 305–310.
- Norhammar A, Tenerz A, Nilsson G, et al. Glucose metabolism in patients with acute myocardial infarction and no previous diagnosis of diabetes mellitus: A prospective study. *Lancet* 2002; 359: 2140–2144.
- Sanjuan R, Nuñez J, Blasco ML, et al. Prognostic implications of stress hyperglycemia in acute ST elevation myocardial infarction. Prospective observational study. *Rev Esp Cardiol* 2011; 64: 201–207.
- Giraldez RR, Clare RM, Lopes RD, et al. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. *Am Heart J* 2013; 165: 918–925.
- American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2013; 36: S67–S74.
- Corpus RA, O'Neill WW, Dixon SR, et al. Relation of hemoglobin A1c to rate of major adverse cardiac events in nondiabetic patients undergoing percutaneous coronary revascularization. *Am J Cardiol* 2003; 92: 1282–1286.
- Timmer JR, Ottervanger JP, Bilo HJ, et al. Prognostic value of admission glucose and glycosylated haemoglobin levels in acute coronary syndromes. *QJM* 2006; 99: 237–233.
- Cakmak M, Cakmak N, Cetemen S, et al. The value of admission glycosylated hemoglobin level in patients with acute myocardial infarction. *Can J Cardiol* 2008; 24: 375–378.
- Timmer JR, Hoekstra M, Nijsten MWN, et al. Prognostic value of admission glycosylated hemoglobin and glucose in nondiabetic patients with ST-segment-elevation myocardial infarction treated with percutaneous coronary intervention. *Circulation* 2011; 124: 704–711.
- Gustafsson I, Kistorp CN, James MK, et al. OPTIMAAL Study Group: Unrecognized glycometabolic disturbance as measured by hemoglobin A1c is associated with a poor outcome after acute myocardial infarction. *Am Heart J* 2007; 154: 470–476.
- Chowdhury TA and Lasker SS. Elevated glycated haemoglobin in non-diabetic patients is associated with an increased mortality in myocardial infarction. *Postgrad Med J* 1998; 74: 480–481.
- Rasoul S, Ottervanger JP, Bilo HJ, et al. Glucose dysregulation in nondiabetic patients with ST-elevation myocardial infarction: Acute and chronic glucose dysregulation in STEMI. *Neth J Med* 2007; 65: 95–100.
- Cieck G, Uyarel H, Ergelen M, et al. Hemoglobin A1c as a prognostic marker in patients undergoing primary angioplasty for acute myocardial infarction. *Coron Artery Dis* 2011; 22: 131–137.
- Thygesen K, Alpert JS, Jaffe AS, et al.; the Writing Group on behalf of the Joint ESC/ACC/AHA/WHF Task Force for Universal Definition of Myocardial Infarction. Third univerDownloaded from acc.sagepub.com by guest on April 8, 2014 Blasco et al. 7 sal definition of myocardial infarction. *J Am Coll Cardiol* 2012; 60: 1581–1598.
- Killip T and Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. *Am J Cardiol* 1967; 20: 457–464.
- Hoelzel W, Weykamp C, Jeppsson JO, et al.; IFCC Working Group on HbA1c Standardization. IFCC reference system for measurement of hemoglobin A1c in human blood and the national standardization schemes in the United States, Japan, and Sweden: A method-comparison study. *Clin Chem* 2004; 50: 166–174.
- Oswald GA and Yudkin JS. Hyperglycaemia following acute myocardial infarction: The contribution of undiagnosed diabetes. *Diabet Med* 1987; 4: 68–70.
- Petursson P, Herlitz J, Caidahl K, et al. Association between glycometabolic status in the acute phase and 21/2 years after an acute coronary syndrome. *Scand Cardiovasc J* 2006; 40: 145–151.
- Liu Y, Yang Y, Zhu J, et al. Prognostic significance of hemoglobin A1c level in patients hospitalized with coronary artery disease. A systematic review and meta-analysis. *Cardiovasc Diabetol* 2011; 10: 98–107.
- Selvin E, Steffes MW, Zhu HBS, et al. Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. *N Engl J Med* 2010; 362: 800–811.
- Kersten JR, Schmeling TJ, Orth KG, et al. Acute hyperglycemia abolishes ischemic preconditioning in vivo. *Am J Physiol* 1998; 275: H721–H725.
- Shechter M, Merz MB and Pau-Labrador MJ. Blood glucose and platelet-dependent thrombosis in patients with coronary artery disease. *J Am Coll Cardiol* 2000; 35: 300–307.
- Timmer JR, Ottervanger JP, De Boer MJ, et al. Hyperglycemia is an important predictor of impaired coronary flow before reperfusion therapy in ST-segment elevation myocardial infarction. *J Am Coll Cardiol* 2005; 45: 999–1002.
- Iwakura K, Ito H, Ikushima M, et al. Association between hyperglycemia and the non-reflow phenomenon in patients with acute myocardial infarction. *J Am Coll Cardiol* 2003; 41: 1–7.
- Lazzeri C, Valente S, Chiostrì M, et al. The glucose dysmetabolism in the acute phase of non-diabetic ST-elevation myocardial infarction: From insulin resistance to hyperglycemia. *Acta Diabetol* 2013; 50: 293–300.
- Sanjuan R, Blasco ML, Martínez-Maicas H, et al. Acute myocardial infarction: High risk ventricular tachyarrhythmias and admission glucose level in patients with and without diabetes mellitus. *Curr Diabetes Rev* 2011; 7: 126–134.
- Oliver MF and Opie LH. Effects of glucose and fatty acids on myocardial ischaemia and arrhythmias. *Lancet* 1994; 343: 155–158.
- Oliver MF. Metabolic causes and prevention of ventricular fibrillation during acute coronary syndromes. *Am J Med* 2002; 112: 305–311.
- Paneni F, Beckman JA, Creager MA, et al. Diabetes and vascular disease: Pathophysiology, clinical consequences, and medical therapy: Part I. *Eur Heart J* 2013; 34: 2436–2446.
- D'Ascenzo F, Biondi-Zoccai G, Moretti C, et al. TIMI, GRACE and alternative risk score in acute coronary syndromes: A meta-analysis of 40 derivation studies on 216,552 patients and of 42 validation studies on 31,625 patients. *Contemp Clin Trials* 2012; 33:

- 507–514.
34. El-Menyar A, Zubaid M, Shehab A, et al. Prevalence and impact of cardiovascular risk factors among patients presenting with acute coronary syndrome in the middle East. *Clin Cardiol* 2011; 34: 51–58.
 35. Abrignani MG, Dominguez LJ, Biondo G, et al. In-hospital complications of acute myocardial infarction in hypertensive subjects. *Am J Hypertens* 2005; 18: 165–170.
 36. Lee D, Goodman SG, Fox KA, et al. Prognostic significance of presenting blood pressure in non-ST-segment elevation acute coronary syndrome in relation to prior history of hypertension. *Am Heart J* 2013; 166: 716–722.